Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Jacob L Goldberg; Fariba Navid; Jacquelyn A Hank; Amy K Erbe; Victor Santana; Jacek Gan; Fenna de Bie; Amal M Javaid; Anna Hoefges; Michael Merdler; Lakeesha Carmichael; KyungMann Kim; Michael W Bishop; Michael M Meager; Stephen D Gillies; Janardan P Pandey; Paul M Sondel

doi:10.1136/jitc-2020-000590

Citation Tools

This article has a correction. Please see:

Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma - June 01, 2020

PDF

XML

Immunotherapy biomarkers

Short report

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Goldberg JL, Navid F, Hank JA, et al

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Journal for ImmunoTherapy of Cancer 2020;8:e000590. doi: 10.1136/jitc-2020-000590

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has a correction. Please see:

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password